FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Innoviva, Inc.		 2. Issuer Name and Ticker or Trading Symbol

Armata Pharmaceuticals, Inc. [ ARMP ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

1350 OLD BAYSHORE HIGHWAY SUITE 400		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/31/2022
(Street)

BURLINGAME, CA 94010
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/31/2022  P  5385208 A$5.00 16365969 I See footnotes (1)(2)
Common Stock         8710800 (1)D (1) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants to Purchase Common Stock (1)(2)$5.00 3/31/2022  P   0    3/31/2022 3/31/2027 Common Stock 2692604 $5.00 2692604 I See footnotes (1)(2)
Warrants to Purchase Common Stock $5.00            (3) (3)Common Stock  (3) 1807396 I See footnote (3)
Warrants to Purchase Common Stock $3.25            (4) (4)Common Stock  (4) 6153847 I See footnote (4)
Warrants to Purchase Common Stock $2.87            (5) (5)Common Stock  (5) 8710800 D (5) 
Explanation of Responses:
(1) See Exhibit 99.1
(2) See Exhibit 99.1
(3) See Exhibit 99.1
(4) See Exhibit 99.1
(5) See Exhibit 99.1

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Innoviva, Inc.
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME, CA 94010		XX

Innoviva Strategic Opportunities LLC
1350 OLD BAYSHORE HIGHWAY SUITE 400
BURLINGAME, CA 94010		XX
Signatures
INNOVIVA, INC., by /s/ Pavel Raifeld, Chief Executive Officer4/1/2022
**Signature of Reporting PersonDate

INNOVIVA STRATEGIC OPPORTUNITIES LLC, by Innoviva, Inc., its managing member, /s/ Pavel Raifeld, Chief Executive Officer4/1/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Armata Pharmaceuticals Charts.
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Armata Pharmaceuticals Charts.